-
公开(公告)号：US20210215676A1
公开(公告)日：2021-07-15
申请号：US17059315
申请日：2019-05-31
申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , UNIVERSITE D'ANGERS , UNIVERSITE DE NANTES , ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS , SORBONNE UNIVERSITE
发明人： Frédéric ALTARE , Guillaume SARRABAYROUSE , Harry SOKOL , Emmanuelle GODEFROY , Francine JOTEREAU
IPC分类号： G01N33/50 , A61K35/17 , G01N33/569
摘要： The invention relates to a method comprising a step of determining the number, concentration and/or proportion of T lymphocytes with a CD4+ CD8ααlow phenotype and further expressing CCR6 and/or CXCR6, for (i) diagnosing, (ii) prognosing outcome of, or (iii) predicting the risk of developing a disease related to a decrease of F. prau. The invention also concerns the treatment of said disease by administering a population of these specific T lymphocytes. The Inventors have indeed identified two markers, CCR6 and CXCR6, enabling to select a population of F. prau-specific cells among CD4+ CD8ααlow T lymphocytes, from a blood sample and without needing to assess their F. prauspecificity. T lymphocytes with a CD4+ CD8ααlow CCR6+ CXCR6+ phenotype are for example significantly decreased in IBD patients. The disease related to a decrease of F. prauis particularly an inflammatory bowel disease (IBD), such as Crohn's disease.
-
52.发明授权公开(公告)号：US11046704B2
公开(公告)日：2021-06-29
申请号：US16742469
申请日：2020-01-14
申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , Centre national de la recherche scientifique , UNIVERSITÉ DE BORDEAUX
IPC分类号： A61K31/555 , A61K31/409 , A61P31/00 , A61P31/12 , A61P31/14 , A61P31/16 , A61P31/18 , A61P31/20 , A61P31/22 , C07D487/22 , A61K31/00
摘要： The present invention concerns metallated porphyrin derivatives as ligands of G-quadruplex and their novel use as anti-viral agents.
-
公开(公告)号：US20210161887A1
公开(公告)日：2021-06-03
申请号：US17045049
申请日：2019-04-03
申请人： Universite de Bretagne Occidentale , Centre Hospitalier Regional Universitaire de Brest , Institut National de la Sante et de la Recherche Medicale (INSERM) , Centre National de la Recherche Scientifique (CNRS) , Institut Curie , Université de Paris , Univ Paris XIII Paris-Nord Villetaneuse , Universite Paris-Saclay
发明人： Marc Blondel , Alicia Quillevere , Cécile Voisset , Maria José Lista , Robin Fahraeus , Chrysoula Daskalogianni , Rodrigo Prado-Martins , Marie-Paule Teulade-Fichou , Anton Granzhan , Claire Beauvineau , Oksana Reznichenko
IPC分类号： A61K31/4709 , A61K45/06 , A61K9/00 , C07D401/14 , C07D471/04 , A61K31/444 , A61K31/506 , A61K31/4745 , A61P31/20 , A61P35/00
摘要： The present invention relates to novel bis-hydrazone derivatives of formula (I): wherein Ar1 and Ar2 may be identical or different and are each independently selected from the group consisting of groups of formula (II) and (III): Y1 and Z1 are independently CH or NRc+, provided that al least one of Y1 and Z1 is NRc+ and at least one of Y1 and Z1 is CH, and Ra, Rb, Rc, X2− and L as defined in the claims, or a hydrate or a solvate thereof. Compositions and kits comprising same are also described. Said bis-hydrazone derivatives of formula (I), compositions and kits are useful as drugs, in particular for treating or preventing cancers associated with the Epstein-Barr Virus.
-
公开(公告)号：US20210154205A1
公开(公告)日：2021-05-27
申请号：US17057141
申请日：2019-05-23
申请人： UNIVERSITE CLAUDE BERNARD LYON 1 , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , ECOLE NORMALE SUPERIEURE DE LYON , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , UNIVERSITE LAVAL
发明人： Manuel ROSA-CALATRAVA , Olivier TERRIER , Claire NICOLAS DE LAMBALLERIE , Guy BOIVIN , Mario Andres PIZZORNO
IPC分类号： A61K31/554 , A61K45/06 , A61P37/04 , A61P31/14 , A61P31/04
摘要： The present invention relates to diltiazem for use as an agent for activating the expression of at least one gene encoding a type III interferon, in the prevention and/or treatment of infections by at least one pathogenic microorganism of the epithelia of the respiratory and/or intestinal tracts.
-
公开(公告)号：US10987524B2
公开(公告)日：2021-04-27
申请号：US15789426
申请日：2017-10-20
申请人： Vermon S.A. , Institut National de la Sante et de la Recherche Medicale (INSERM), U1032 , Universite Pierre Et Marie Curie (Paris 6) , CarThera S.A.S.
发明人： Alexandre Carpentier , An Nguyen-Dinh , Jean-Yves Chapelon , Rémi Dufait , Christophe Notard , Françoise Chavrier , Cyril Lafon , Michael Canney , William Apoutou N'Djin
摘要： An interstitial ultrasound thermal ablation applicator for conformal treatment of an inhomogeneous tumor lesion includes: a body having a longitudinal axis; and a plurality of array transducers mounted on the body, arranged side by side and having azimuth directions parallel to the longitudinal axis of the body, and having outer faces disposed in a polygonal arrangement; the plurality of array transducers having predetermined elevation dimensions defined for directing emitted ultrasonic energy to obtain a conformal volume treatment of the tumor lesions. An electronic driving method for driving an applicator having multiple independent transducer elements arranged in rows and columns includes: controlling focal parameters of each row and column of transducer elements; and controlling a contribution of each row and column of transducer elements in a manner to provide a conformal ablated volume.
-
56.发明授权公开(公告)号：US10859577B2
公开(公告)日：2020-12-08
申请号：US15038125
申请日：2014-11-24
申请人： Institut de Cancerologie de L'Ouest , Universite D'Angers , Institut National de la Sante et de la Recherche Medicale (INSERM)
IPC分类号： G01N33/574 , G01N33/50
摘要： The present invention is in the technical field of breast cancer management, and more particularly relates to the diagnosis and/or prognosing of triple-negative breast cancer (TNBC). The invention is more particularly based on the finding that specific biomarkers are abberantly expressed in patients suffering from a triple-negative breast cancer recurrence, and are highly related to the aggressiveness of this disease, and thus to survival of said patient.
-
公开(公告)号：US10858306B2
公开(公告)日：2020-12-08
申请号：US16844077
申请日：2020-04-09
申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , UNIVERSITE DE NANTES , UNIVERSITE D'ANGERS , THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
IPC分类号： C07C201/12 , C07C67/307 , C07C41/18 , C07B59/00 , C07C247/10 , C07C247/16 , C07D207/46 , C07C253/30 , C07C25/24 , C07C17/361 , C07C43/225 , C07C29/62 , C07C29/10 , C07C29/58 , C07C33/46
摘要： The present invention concerns a method of synthesizing a iodo- or astatoarene comprising the reaction of a diaryliodonium compound with a iodide or astatide salt, respectively. The invention also relates to said iodo- or astatoarene and diaryliodonium compound as such. The invention also concerns a method of synthesizing a iodo- or astatolabelled biomolecule and/or vector using said iodo- or astatoarene.
-
58.发明申请公开(公告)号：US20200377892A1
公开(公告)日：2020-12-03
申请号：US16643293
申请日：2018-08-31
申请人： INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , HOSPICES CIVILS DE LYON , Centre Léon-Bérard , Centre national de la recherche scientifique , Université Claude Bernard Lyon 1
IPC分类号： C12N15/113
摘要： The present invention concerns an inhibitor for use for preventing and/or treating an infection with hepatitis B virus (HBV) and an in vitro screening method for the identification of a candidate compound suitable for preventing and/or treating an infection with hepatitis B virus. Inventors show that the knock-down of histone chaperone HIRA before HBV inoculation led to a strong decrease in HBV cccDNA (covalently closed circular DNA) accumulation and stable rcDNA (relaxed circular DNA) levels, in HepG2-NTCP cell line, indicating either a possible incomplete or delayed rcDNA to cccDNA transition. This effect was independent from HBx protein expression in Primary human hepatocytes (PHH). HIRA is able to interact with cccDNA and its recruitment is concomitant with deposition of histone variant H3.3 in HepG2-NTCP cell line. HIRA was able to interact with HBc (HBV capsid protein) in infected hepatocytes and in an HepaRG cell line expressing HBc in an inducible manner.
-
59.发明申请公开(公告)号：US20200347457A1
公开(公告)日：2020-11-05
申请号：US16758624
申请日：2018-10-24
申请人： UNIVERSITE PARIS DESCARTES , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S)
IPC分类号： C12Q1/6886
摘要： This invention relates to a method for diagnosing and/or prognosticating HER2-dependent cancer in a subject, comprising a) measuring the amount of one or more miRNA selected from the group consisting of miRNA 429-3p, miRNA 29c-3p, miR-NA 29a-3p, miRNA 29b- 3p, miRNA 200a-3p, miRNA 200b-3p, miRNA 200c-3p, miRNA 141-3p, miRNA 15a-5p, miRNA 15b-5p, miRNA 16-5p, miRNA 424-5p, miRNA 497-5p, miRNA 615-3p, miRNA 451a-3p and miRNA 542-5p in a sample from the subject; b) comparing the amount of one or more miRNA measured in step a) to a reference value; c) finding a deviation or no deviation of the amount of one or more miRNA measured in step a) from the reference value; and d) attributing said finding of deviation or no deviation to a particular diagnosis and/or prognosis of HER2-dependent cancer in the subject.
-
60.发明申请公开(公告)号：US20200339986A1
公开(公告)日：2020-10-29
申请号：US16758274
申请日：2018-10-24
申请人： UNIVERSITE PARIS DESCARTES , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)
IPC分类号： C12N15/113
摘要： This invention relates to an agent that modulates the activity of a micro ribonucleic acid (miRNA), said miRNA being selected from the group consisting of miRNA 429-3p, miRNA 29c-3p, miRNA 29b-3p, miRNA 200a-3p, miRNA 200b-3p, miRNA 200c-3p, miRNA 141-3p, miRNA 15a-5p, miRNA 15b-5p, miRNA 16-5p, miRNA 424-5p, miRNA 497-5p, miRNA 615-3p, miRNA 451a-5p and miRNA 542-5p, for use in the treatment of HER2-dependent cancer.
-
-
-
-
-
-
-
-
-
搜索结果
705 条记录 (耗时 0.041 秒)
